Zelira Therapeutics(ASX:ZLD ) Managements

  • Symbol:ASX:ZLD
  • Sector:Healthcare
  • Industry:Pharmaceutical
  • CEO:Richard Hopkins
  • Founded:2003
Categories:

Zelira Therapeutics(ASX:ZLD ) Managements

Osagie Imasogie

Chairman

Mr. Imasogie is the Co-Founder and Senior Managing Partner of PIPV Capital with over 30 years of experience in the fields of law, finance and business management, healthcare and the pharmaceutical industry. Prior to co-founding PIPV Capital, Osagie conceptualized and established GlaxoSmithKline Ventures in which he led his team in investing GSK R&D non-progressed assets into various companies and/or as the basis of starting new companies. Prior to this role within GSK, Osagie was a Vice President for Product Development Strategy at SmithKline Beecham.

Prior to this role at SmithKline, he was the Founding Senior Vice President for Business Development and General Counsel at Endo Pharmaceuticals. He also previously served as a DuPont Merck Vice President for International Sales and Marketing and General Counsel to DuPont Merck’s International, Manufacturing and Generic Drug Divisions. Osagie has been a serial entrepreneur and has been founder and former CEO and/or Chairman of multiple life sciences companies, including Ilera Healthcare, iCeutica, Churchill Pharmaceuticals, Ception Therapeutics and Trigenesis Therapeutics. Osagie has also been a Corporate Finance Partner in Price Waterhouse and a practicing attorney in a major US Law Firm.

Osagie is active in charitable and community pursuits and serves as a member of the Board of the Philadelphia Orchestra and the Philadelphia Museum of Art. Osagie is an Adjunct Professor at the University of Pennsylvania Law School and also serves on the Law School’s Board of Overseers. In addition, he is a member of the Board of Trustees of the University of Pennsylvania and serves as the Chairman of the Budget & Finance Committee in addition to being a member of the Executive Committee. Osagie is a member of the New York State Bar.
Harry Karelis

Deputy Chairman

Mr Karelis graduated from The University of Western Australia with Bachelors and Honours in Science majoring in Biochemistry and Microbiology as well as a Masters in Business Administration. He is a Fellow of the Financial Services Institute of Australia, a Fellow of the Australian Institute of Company Directors and has qualified as a Chartered Financial Analyst (CFA) from the CFA Institute in the United States.

He has in over 25 years’ diversified experience in the financial services sector including fundamental analysis, funds management and private equity investing and has acted as a director on several public and private companies in Australia, Singapore and the United Kingdom. Harry resides in Australia.
Dr. Richard Hopkins

Managing Director ex USA

Dr Hopkins is an experienced bio-pharmaceutical executive with over 11 years in corporate leadership roles with public biotechnology companies. He has an established track record in drug development of novel cancer therapies and has strong experience with corporate strategy, business development and intellectual property matters. During his career Dr Hopkins has managed and overseen several strategic alliance and licensing deals with global pharmaceutical partners.

Most recently, he was the Chief Executive Officer of PharmAust Ltd, an ASX-listed biotechnology company. Prior to that, he was Managing Director at Phylogica Ltd, a company he co-founded in 2001 where he also held a variety of other positions including Chief Scientific Officer and Chief Operating Officer.

Richard holds a PhD in Molecular Biology, is an author on over 25 peer-reviewed publications and is an inventor on 17 patents and patent applications. Dr Hopkins currently serves as a member of the Western Australian Ausbiotech Committee.

Investor Presentation

The latest update from the company

Click Here
Stay updated about
this company

Become a Patron below and support us in covering the latest marijuana news!